CBAY - Earnings announcements

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera

NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701. To access the live and subsequently archived webcast of the conference call, go t

Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) Normalization of alkaline phosphatase at 12 months was achieved by 25.0% of patients treated with seladelpar vs. 0% on placebo (p<0.0001) In patients having moderate-to-severe itch at baseline, the seladelpar treated group improved their pruritus at 6 months compared to those in the placebo group (p<0.005) Safety and tolerability were comparable between placebo and seladelpar groups and consistent with previous studies CymaBay will hold a conference call to discuss these results today at 8:00 a.m. ET N

NEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will host an investor call on Thursday, September 7 at 8:00 a.m. ET to share topline results from the Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC). To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13741034. To access the live and archived webcast of the conference call, go to the Investors section of t

Top-line data from RESPONSE Phase 3 study in PBC expected by end of September 2023 IDEAL clinical trial actively recruiting Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023. Sujal Shah, President and CEO of CymaBay, stated, "I'm incredibly proud of the progress our teams have made thus far this year as we march towards our key and exc

NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the confer

Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of seladelpar in patients with PBC published in Hepatology Completed a public equity offering totaling net proceeds of $92.4 million Entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases, today announced corp

NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference c

NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022. Sujal Shah, President and CEO of CymaBay, stated, "We are off to a fast start in 2023 after making significant progress in 2022 in our development program evaluating seladelpar for patients with primary biliary cholangitis (PBC). Since completing enrollment in RESPONSE, our global phase 3 registration study, in July 2022, we presented data at The Liver Me

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID # 13736281. To access the live and subsequently archived webcast

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the third quarter ended September 30, 2022. Sujal Shah, President and CEO of CymaBay, stated, "Early in the third quarter we completed enrollment in RESPONSE, our global registration study of seladelpar in patients with PBC. This achievement was a direct result of the tireless efforts of our teams and the relationships we have been fortunate to leverage among partners, health care providers and patie

NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2022 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 855-327-6837 from the U.S. and Canada, or 631-891-4304 internationally, Conference ID #10020554. To access the live and subsequently archived webcast of the c

Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2022. Sujal Shah, President and CEO of CymaBay, stated, "We are elated to have finished enrollment in RESPONSE, our second, global Phase 3 study of seladelpar for patients with primary biliary cholangitis (PBC). We enrolled 19

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID#13730902. To access the live and subsequently archived webcast of the conferen

Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial Results from a 52-week, open-label phase 2 study of seladelpar in patients with PBC published in the Journal of Hepatology Biopharma leader, Éric Lefebvre, M.D. appointed to the Board of Directors Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the first quarter ended March 31, 2022. Sujal Shah, President and CEO of CymaBay, stated

NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, May 12, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2022 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID#13728967. To access the live and subsequently archived webcast of the conference

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth quarter and fiscal year ended December 31, 2021. Sujal Shah, President and CEO of CymaBay, stated, "2021 was a year of growth for CymaBay and included accomplishments that position CymaBay for long-term success. A non-dilutive, risk-sharing development financing agreement of up to $100 million signed with Abingworth in July, together with a $75 million public equity offering in November support t

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 17, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2021 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13726915. To access the live and subsequently archived webcast o

Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC) Additional data from prior studies of seladelpar in patients with PBC to be featured at The Liver Meeting® November 12-15, 2021 held by the American Association for the Study of Liver Diseases (AASLD) CymaBay to host Post-AASLD KOL call on November 15 at 4:30pm ET Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today ann

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2021 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13723498. To access the live and subsequently archived webcast of

NEWARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including Citi's 16th Annual BioPharma Virtual Conference taking place September 8-10, 2021, the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 and the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2021. Citi's 16th Annual BioPharma Virtual ConferenceDate:Thursday, September 9Time:1-on-1 meetings only  H.C

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical trial Actively recruiting patients in two global, clinical studies evaluating seladelpar in PBC RESPONSE, a 52-week, randomized, placebo-controlled, Phase 3 registrational studyASSURE, an open-label, long-term study Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapi

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13720877. To access the live and subsequently archived webcast of the confere